VimRx Pharmaceuticals Inc. said Thursday that the FDA hasapproved a new dosing schedule for its Phase I trial ofVimRxyn in AIDS patients.
The action will enable the trial to resume, and the Stamford,Conn., company (NASDAQ:VMRX) said it will begin enrollingnew patients soon. The trial, sponsored by the NationalInstitutes of Health, was suspended after the anti-viral drugcaused cutaneous discomfort in the patients.
VimRx shares were up 19 cents to $2.81.
VimRxyn is an organic compound based on hypericin, a plantderivative of St. John's wort, and is thought to interfere withviral replication. The Illinois Institute of Technology isconducting preclinical testing of hypericin to treat Herpessimplex virus types 1 and 2. VimRx is also developing an oralformulation. -- KB
(c) 1997 American Health Consultants. All rights reserved.